After scandals, China proposes new fines in bid to shore up domestic vaccine industry

Authorities in China proposed new fines specific to vaccine manufacturing and testing. (Pixabay)

After China’s latest vaccine scandal that resulted in more than a dozen arrests and a $1.3 billion fine for a domestic manufacturer, authorities in the country have rolled out proposals to crack down on future vaccine violations.

China’s State Administration for Market Regulation on Sunday posted notice of a draft law to regulate vaccine production, distribution and use. China is soliciting feedback on the proposal until Nov. 25.

Fines would be applicable when companies submit false test results, don't recall batches that failed testing or for other violations. Officials are proposing a sliding scale for fines based on the seriousness of the offense. It’s the first regulatory approach in China specific to vaccines after a series of scandals eroded trust in vaccines in the country in recent years.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

For the most serious offenses, fines could be up to 10 times the product's market value, according to the proposal.

RELATED: China slaps monstrous $1.3B penalty on vaccine scandal culprit Changsheng 

This summer, Chinese regulators found data integrity problems during a surprise inspection at Changchun Changsheng Life Sciences, triggering a nationwide controversy over rabies vaccines that led to arrests of company executives, plus resignations, demotions and firings for government officials. During the scandal, citizens took to social media to voice distrust in China’s domestic drug industry, prompting President Xi Jinping and Premier Li Keqiang to respond.

Officials eventually fined the company $1.3 billion and reinspected every other vaccine maker in the country, later clearing them.

RELATED: China’s illegal vaccine sales culprit gets 19 years in prison

The Changsheng episode followed another scandal in China in 2016, when officials discovered that an illegal vaccine ring distributed potentially unsafe vaccines in the Shandong Province for years. The leader of the scheme, Pang Hongwei, received a 19-year prison sentence. In reaction to the scandal, Chinese authorities arrested 324 people and removed or demoted 357 government officials. The situation exposed loopholes in the country’s vaccine distribution system, and lawyers afterward called on the country to bolster its laws to support vaccine safety.


Suggested Articles

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.